Listen as Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute in Edmonton Alberta, discusses the ways in which targeted therapeutics have affected how clinical trials are now conducted, and how increased collaboration among several early phase investigative sites in Canada has led to higher enrolment for several trials.
He also offers advice to oncology sponsors on how they can improve collaboration with sites to speed up start-up times. You will hear why Canada’s centralized healthcare system is ideally suited for both novel, early phase trials as well as for expansion of phase III trials facing recruitment hurdles in the United States.
Listen To Interview
Sign up to